The CD39 positive hepatitis B virus surface protein (HBVs)-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-hepatocellular carcinoma (HCC) activity
The CD39 positive hepatitis B virus surface protein (HBVs)-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-hepatocellular carcinoma (HCC) activity
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now